BRCA1 and pancreatic neoplasm: Thus, to explore the novel mechanisms of resistance to PARP inhibitors, we constructed BRCA1 KO pancreatic cancer cells (C1 cells) and then derived an olaparib-resistant clone (C1/OLA cells) from these cells.